The ASCENDE-RT trial has released 15-year follow-up results, providing important insights into survival outcomes for patients with high-risk prostate cancer. Researchers studied the long-term effects of combining radiation therapy with hormone treatment in men at elevated risk of recurrence.
Findings suggest that while aggressive treatment strategies can improve disease control, the overall survival benefit varies depending on individual patient factors such as age, tumour stage, and overall health. Side effects, including urinary and bowel complications, were closely monitored over the extended follow-up period.
Doctors emphasise that personalised treatment remains key. High-risk patients may benefit from combined therapies, but clinicians must weigh potential gains against long-term quality-of-life considerations. Routine monitoring and tailored interventions can help optimise outcomes.
The study reinforces the importance of evidence-based decision-making in prostate cancer management. Medical experts urge patients to discuss long-term risks and benefits with their healthcare providers before choosing aggressive treatments.
These results contribute to evolving clinical guidelines and help refine strategies for managing high-risk prostate cancer while minimising adverse effects over time.
